TreeFrog Therapeutics secures $75M in Series B financing to advance a pipeline of stem cell-derived cell therapies and deploy proprietary C-Stem™ technology in the USA & Japan

TreeFrog Therapeutics, a privately held French-based biotech startup focused on developing safe and affordable stem cell-derived cell therapies for millions of patients, today announced the successful closing of a $75 million (€64M) Series B financing round, bringing the total funding to date to $83 million...